497 related articles for article (PubMed ID: 15486569)
1. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.
Wilding J; Van Gaal L; Rissanen A; Vercruysse F; Fitchet M;
Int J Obes Relat Metab Disord; 2004 Nov; 28(11):1399-410. PubMed ID: 15486569
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension.
Tonstad S; Tykarski A; Weissgarten J; Ivleva A; Levy B; Kumar A; Fitchet M
Am J Cardiol; 2005 Jul; 96(2):243-51. PubMed ID: 16018851
[TBL] [Abstract][Full Text] [Related]
3. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects.
Astrup A; Caterson I; Zelissen P; Guy-Grand B; Carruba M; Levy B; Sun X; Fitchet M
Obes Res; 2004 Oct; 12(10):1658-69. PubMed ID: 15536230
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Toplak H; Hamann A; Moore R; Masson E; Gorska M; Vercruysse F; Sun X; Fitchet M
Int J Obes (Lond); 2007 Jan; 31(1):138-46. PubMed ID: 16703004
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients.
Rosenstock J; Hollander P; Gadde KM; Sun X; Strauss R; Leung A;
Diabetes Care; 2007 Jun; 30(6):1480-6. PubMed ID: 17363756
[TBL] [Abstract][Full Text] [Related]
6. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.
Bray GA; Hollander P; Klein S; Kushner R; Levy B; Fitchet M; Perry BH
Obes Res; 2003 Jun; 11(6):722-33. PubMed ID: 12805393
[TBL] [Abstract][Full Text] [Related]
7. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.
Eliasson B; Gudbjörnsdottir S; Cederholm J; Liang Y; Vercruysse F; Smith U
Int J Obes (Lond); 2007 Jul; 31(7):1140-7. PubMed ID: 17264849
[TBL] [Abstract][Full Text] [Related]
8. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
[TBL] [Abstract][Full Text] [Related]
9. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes.
Stenlöf K; Rössner S; Vercruysse F; Kumar A; Fitchet M; Sjöström L;
Diabetes Obes Metab; 2007 May; 9(3):360-8. PubMed ID: 17391164
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J;
Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356
[TBL] [Abstract][Full Text] [Related]
11. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.
Dodick DW; Freitag F; Banks J; Saper J; Xiang J; Rupnow M; Biondi D; Greenberg SJ; Hulihan J;
Clin Ther; 2009 Mar; 31(3):542-59. PubMed ID: 19393844
[TBL] [Abstract][Full Text] [Related]
12. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
Muls E; Kolanowski J; Scheen A; Van Gaal L;
Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
[TBL] [Abstract][Full Text] [Related]
13. Topiramate: a new potential pharmacological treatment for obesity.
Astrup A; Toubro S
Obes Res; 2004 Dec; 12 Suppl():167S-73S. PubMed ID: 15687413
[TBL] [Abstract][Full Text] [Related]
14. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
[TBL] [Abstract][Full Text] [Related]
15. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH
Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
[TBL] [Abstract][Full Text] [Related]
16. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study.
Aronne LJ; Tonstad S; Moreno M; Gantz I; Erondu N; Suryawanshi S; Molony C; Sieberts S; Nayee J; Meehan AG; Shapiro D; Heymsfield SB; Kaufman KD; Amatruda JM
Int J Obes (Lond); 2010 May; 34(5):919-35. PubMed ID: 20157323
[TBL] [Abstract][Full Text] [Related]
17. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type.
Roy Chengappa K; Kupfer DJ; Parepally H; John V; Basu R; Buttenfield J; Schlicht P; Houck P; Brar JS; Gershon S
Bipolar Disord; 2007 Sep; 9(6):609-17. PubMed ID: 17845276
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study.
Silberstein SD; Hulihan J; Karim MR; Wu SC; Jordan D; Karvois D; Kamin M
Clin Ther; 2006 Jul; 28(7):1002-11. PubMed ID: 16990078
[TBL] [Abstract][Full Text] [Related]
19. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial.
Winner P; Pearlman EM; Linder SL; Jordan DM; Fisher AC; Hulihan J;
Headache; 2005; 45(10):1304-12. PubMed ID: 16324162
[TBL] [Abstract][Full Text] [Related]
20. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]